Notification letter and reply form to registered shareholders: notice of publication of interim report 2026
Filed with HKEX · Stock code 2096 · · 2 pages · English
The Current Corporate Communication of the Company have been published in English and Chinese languages and are available on the website of the Company at www.simcere.com and the HKEXnews website at www.hkexnews.hk. If you are a new registered shareholder (i.e. if you previously have not received the Company’s letter in relation to seeking your preference on means of receipt of Corporate Communica
Simcere Pharmaceutical Group Limited on 6ix
Earlier from Simcere Pharmaceutical
- 2026 Interim report
- (Revised) Next Day Disclosure Return
- Simcere Zaiming Enters Exclusive License Agreement with Roche for SIM0660 Global Development
- Simcere Pharmaceutical Enters into a Research Collaboration Agreement with Stanford Medicine to Develop Innovative Therapies for Patients with Idiopathic Pulmonary Fibrosis
- Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease
Later from Simcere Pharmaceutical
- Notification letter and reply form to non-registered holders: notice of publication of interim report 2026
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Next Day Disclosure Return
Follow Simcere Pharmaceutical into a list and get an email when it puts out news.
Follow Simcere Pharmaceutical